Cannabis Science Reports: Three Former Federal Law Enforcement Agents Want To Legalize Marijuana Through Washington State Initiative 502

Published on Monday, 19 December 2011 12:05 Written by TradersHuddle Staff

COLORADO SPRINGS, Colo.-( Business Wire )-

Cannabis Science, Inc. (OTCBB: CBIS) a pioneering US biotech company developing pharmaceutical cannabis products, is very pleased to report that two former US Attorneys, and the former head of Seattle FBI, are in favor of Washington State Initiative 502 to legalize marijuana.

On Seattle television King 5 News, two former US attorneys, John McKay and Kate Pflaumer and the former head of Seattle FBI, Charles Mandigo, spoke out on why they think it’s time to change the federal law and to legalize of marijuana.

Pflaumer stated, “It’s a policy position that has become obvious to me over 35 years working in criminal law enforcement and criminal law defense.”

Even though both US attorneys agree that it’s a bad policy, they said it was their job to enforce the law.

Former head of Seattle FBI, Charles Mandigo says he does not condone the use of marijuana, but he supports the initiative, because he feels strongly that the illegal drug trade and the resulting violence is destroying to our society.

Please visit:

http://www.king5.com/news/up-front/Is-it-time-to-legalize-marijuana-135827158.html

and below to view the interviews in their entirety.

http://www.king5.com/news/up-front/video-extra/Up-Front-Extra-After-the-marijuana-interview-135776533.html

State laws vary greatly, but under Federal law cultivation, possession, or sale of any amount, for any purpose, remain illegal. Washington State’s Initiative 502 would allow persons 21 and over to have in their possession either 1 ounce of dried marijuana, 16 ounces of marijuana infused food, or 72 ounces in a liquid form. The state’s Liquor Control Board would manage the system and the estimated income could be over $215 million per year. The state’s DUI laws would be extended to cover driving under the influence of marijuana.

Regarding concerns that the taxes being imposed would so high that this new law would not end the black market for sales, Mandigo replied, “I don’t think that’s the case, I think that most American people want to be law abiding, and given an opportunity to purchase marijuana in a regulated scheme, and not violate the law, that they would choose that as an option. Further if you are selling it under a regulated scheme, you have quality control and you know exactly what the substance is that is being sold and… at a regulated point-of-sale, that you can impose warning labels like you do for the sale of alcohol or tobacco.”

Some people fear that legalization might lead to marijuana becoming available in other places such as grocery stores, as did alcohol. Former US Attorney John McKay said, “The question is whether we should continue criminal prohibition of marijuana... for any amount for any reason. Is that successful? I don’t think so. We have a huge number of persons who smoke marijuana and obtain it illegally and the proceeds go to drug cartels. Better for us to look now at a scheme that we regulate, that we tax, and maintain criminal penalties.”

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science Inc.Robert Kane, 1-561-234-6929Investor Relations Managementinfo@cannabisscience.comwww.cannabisscience.comorDr. Robert J. Melamede, 1-888-889-0888President & This e-mail address is being protected from spambots. You need JavaScript enabled to view it.